

8 July 2016

## GlucoControl for type 2 diabetes named Product of the Month by Retail Pharmacy

### Highlights

- Retail Pharmacy Magazine named Omniblend Innovation's GlucoControl as 'Product of the Month'
- Marketing programs ramping up with product availability
- Dr Ross Walker hosting 'Diet for Diabetes' educational seminar in Melbourne on July 12

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on its portfolio company, Omniblend Innovation, the medical technology company focused on foods for special medical purposes. EVE currently holds a ~25% interest in Omniblend Innovation which is expected to increase to a ~40% holding by 30 September 2016.

### Product of the Month

EVE is pleased to report that Faulding's GlucoControl for use in the dietary management of type 2 diabetes and pre-diabetes, has been recognised as 'Product of the Month' for July by the Retail Pharmacy Magazine. Retail Pharmacy magazine is a trade magazine within the pharmacy industry that has been running for 25 years.



Picture 1: Faulding GlucoControl™, Retail Pharmacy's 'Product of the Month'

The article states:

"The first-to-market product was developed by Melbourne-based company Omniblend Innovation and its team of medical researchers and food scientists, and has been tested and validated under guidance of Professor Peter Clifton, Head of Baker IDI Heart and Diabetes Institute's Nutrition Intervention Laboratory. Omniblend, which manufactures GlucoControl in Australia, won a major government grant to help commercialise the product in 2012.

Unlike other pre-meal drinks, it contains only 16g of protein, measures around 155ml when mixed and can be taken immediately before, or up to 30 minutes before, a meal.

Faulding GlucoControl is available in Chemmart and independent pharmacies now."

### Promotional and Educational 'Diet for Diabetes' Seminars

On Tuesday July 12<sup>th</sup>, Omniblend Innovation will host the second in its series of 'Diet for Diabetes' seminars. The evening will be hosted by Dr Ross Walker, one of Australia's leading preventative health experts who has a weekly

radio show on 2UE as well as appearing in regular segments on other radio channels and television appearances on the Today Show, A Current Affair and Sky News.

The event will include a panel discussion and Q&A session with Dr Walker and Professor Peter Clifton, a prominent endocrinologist who is now a Professor of Nutrition at the University of South Australia. The seminar is targeted at medical practitioners, pharmacists, dieticians and diabetes educators.

**Ends**

#### **About EVE Investments**

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit [www.eveinvestments.com.au](http://www.eveinvestments.com.au) and follow us on Twitter @EVEInvestments

#### **About Omniblend Innovation**

Omniblend Innovation is a private Melbourne based company developing evidence-based dietary interventions to improve the lives of people with common chronic diseases such type-2 diabetes and low blood pressure (hypotension).

In 2016 the Company launched its maiden product, Faulding's GlucoControl for use in the dietary management of type 2 diabetes and pre-diabetes.

For more information, please visit [www.obinnovation.com.au](http://www.obinnovation.com.au)

#### **For more information:**

Bill Fry

Executive Director

+61 8 6465 5500

[billf@eveinvestments.com.au](mailto:billf@eveinvestments.com.au)